Scandinavian Journal of Gastroenterology最新文献

An indication-based analysis of the yield and findings of esophageal high-resolution manometry.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-07 DOI: 10.1080/00365521.2025.2475083

Amir Mari, Sari Cohen, Jamelah Abo Amer, Mohammed Hijazi, Basem Hijazi, Fadi Abu Baker, Edoardo Savarino, Atallah Mansour, Daniela Malkin, Haim Shirin, Daniel L Cohen

{"title":"An indication-based analysis of the yield and findings of esophageal high-resolution manometry.","authors":"Amir Mari, Sari Cohen, Jamelah Abo Amer, Mohammed Hijazi, Basem Hijazi, Fadi Abu Baker, Edoardo Savarino, Atallah Mansour, Daniela Malkin, Haim Shirin, Daniel L Cohen","doi":"10.1080/00365521.2025.2475083","DOIUrl":"https://doi.org/10.1080/00365521.2025.2475083","url":null,"abstract":"Background: High-resolution manometry (HRM) is the gold standard for the diagnosis of esophageal motility disorders. While studies have previously reported on HRM findings in patients with dysphagia and/or chest pain, we sought to compare the yield and findings of HRM based on different indications for motility testing.Methods: A retrospective study was performed including all successful HRM studies performed at two tertiary medical centers between 2018 and 2023. The indication was categorized as either: (1) dysphagia; (2) GERD evaluation; (3) non-cardiac chest pain; (4) epigastric pain; (5) regurgitation/vomiting; or (6) prior to esophageal surgery. Motility disorders were diagnosed as per the Chicago Classification, version 4.0.Results: A total of 768 patients were included (mean age 55.5 +/- 17.3; 56.2% female). The most common indications were dysphagia (368, 47.9%) and prior to reflux testing (267, 34.8%). Normal motility was found in 417 (54.3%) patients while a motility disorder was diagnosed in 351 (45.7%) subjects. A major motility disorder was found in 178 (23.2%) cases, with achalasia in 82 (10.7%) patients. HRM diagnoses significantly differed based on the indication for testing (p < 0.001), with major motility disorders and achalasia being most commonly diagnosed when performed for dysphagia and recurrent regurgitation/vomiting. The indication affected the likelihood of having any motility disorder (p = 0.010), a major motility disorder (p < 0.001), a disorder of EGJ Outflow (p < 0.001), and achalasia (p < 0.001).Conclusions: The indication for HRM testing affects the likelihood of having a motility disorder including achalasia. The highest yield is in patients being evaluated for dysphagia and regurgitation/vomiting.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-7"},"PeriodicalIF":1.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of novel biomarkers for gastric adenocarcinoma through two-sample Mendelian randomization analysis of the human plasma proteome.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-07 DOI: 10.1080/00365521.2025.2472198

Jingjing Tian, Qingrui Cai, Shiying Li, Zhanfei Guo, Yanbao Liu, Zhiwei Zhang, Zhongchao Huo

{"title":"Identification of novel biomarkers for gastric adenocarcinoma through two-sample Mendelian randomization analysis of the human plasma proteome.","authors":"Jingjing Tian, Qingrui Cai, Shiying Li, Zhanfei Guo, Yanbao Liu, Zhiwei Zhang, Zhongchao Huo","doi":"10.1080/00365521.2025.2472198","DOIUrl":"https://doi.org/10.1080/00365521.2025.2472198","url":null,"abstract":"Background: Papillary gastric adenocarcinoma (PGC), a histological subtype of gastric cancer (GC), is characterized by malignant potential and poor prognosis. Therefore, identifying novel biomarkers is urgently needed to enhance PGC diagnosis and treatment outcomes.Methods: This study utilized two-sample Mendelian randomization (MR) to explore potential causal relationships between human blood plasma proteins and GC. Heterogeneity testing, pleiotropy assessment, and directionality analyses were performed to evaluate identified plasma proteins. Additionally, pathway enrichment analysis was conducted to elucidate the molecular mechanisms underlying the causal associations between plasma proteins and GC development.Results: MR analysis of 4,907 plasma proteins related to GC risk identified 90 proteins with potential causal relationships. The findings revealed that DNAJB9, CHCHD10, and suppressor of cytokine signaling 3 exhibited protective effects against GC, while Syntaxin-8, alcohol dehydrogenase 7, and UDP-glucose 4-epimerase were associated with increased GC risk at the genetic level.Conclusion: In the present study, the six plasma proteins identified through comprehensive MR analysis may serve as potential biomarkers for GC, offering new insights for future molecular diagnosis and therapeutic strategies.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-11"},"PeriodicalIF":1.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term use of colchicine is associated with incident cirrhosis: a real-world cohort study.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-06 DOI: 10.1080/00365521.2025.2475488

Mohammad E Naffaa, Fadi Hassan, Helana Jeries, Dikla Dror, Vered Rozenberg, Gabriel Chodick, Michal Carmiel

{"title":"Long-term use of colchicine is associated with incident cirrhosis: a real-world cohort study.","authors":"Mohammad E Naffaa, Fadi Hassan, Helana Jeries, Dikla Dror, Vered Rozenberg, Gabriel Chodick, Michal Carmiel","doi":"10.1080/00365521.2025.2475488","DOIUrl":"https://doi.org/10.1080/00365521.2025.2475488","url":null,"abstract":"Introduction: Chronic effect of colchicine on the liver was not studied enough. We aimed to examine the association between long term colchicine use and incident cirrhosis among new colchicine initiators.Study: Using database of Maccabi Healthcare Services (MHS), we included all patients aged ≥18 years old who initiated colchicine between 1 January 2000 and 31 December 2018 and followed them until the earliest of the following: incident cirrhosis, leaving MHS, death or 31 December 2020. Incident cirrhosis was diagnosed according to ICD-9 code. We defined incident decompensated cirrhosis as the first presentation of cirrhosis, once ascites, encephalopathy and/or variceal bleeding were diagnosed within a period of 90 days before until 90 days after incident cirrhosis. Exposure to colchicine was evaluated in two manners: proportion of months covered (PMC) and mean daily dose (MDD).Results: A total of 21,773 eligible patients were included. We identified 129 incident cases of cirrhosis. Seventy-six (59%) had decompensated cirrhosis, as a first clinical presentation of cirrhosis. Familial Mediterranean Fever (FMF), BMI > 40, FIBROSIS-4 (FIB-4) score and colchicine PMC were all significantly associated with incident cirrhosis. Patients in '60-80%' PMC group had the highest risk for developing cirrhosis (hazard ratio (HR) 3.68, 95% confidence interval (CI) 2.23-6.07). The risk was higher for patients on colchicine >60 months (HR 6.69, 95% CI 3.56-12.56).Conclusions: long term colchicine use is associated with incident cirrhosis, mainly with decompensation at the time of diagnosis. Long term colchicine treatment should be limited to diseases with no other alternative, such as FMF.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-7"},"PeriodicalIF":1.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic evaluation of preventing gastric cancer by eliminating Helicobacter pylori infection in China.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-04 DOI: 10.1080/00365521.2025.2473020

Yan Li, Shengwen Zhu, Yashi Liu, Dezhi He, Yanliang Liu, Hongchao Li

{"title":"Economic evaluation of preventing gastric cancer by eliminating Helicobacter pylori infection in China.","authors":"Yan Li, Shengwen Zhu, Yashi Liu, Dezhi He, Yanliang Liu, Hongchao Li","doi":"10.1080/00365521.2025.2473020","DOIUrl":"https://doi.org/10.1080/00365521.2025.2473020","url":null,"abstract":"Objective: To analyze the cost-effectiveness of screening Helicobacter pylori (H. pylori) and determine the optimal screening strategy in China.Methods: A Markov model was used to assess the cost-effectiveness of 13 screen-and-treat strategies, varying starting ages (20, 30, 40) and screening frequencies (no screening, once per lifetime, every 2, 3, or 5 years until age 50). For each scenario, 1,000,000 individuals were simulated. Outcomes were costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), and the number needed to treat (NNT) to prevent a gastric cancer. Deterministic and probabilistic sensitivity analyses tested the model's robustness.Results: Compared with no screening, screening at 20, 30, and 40 years of age once per lifetime were all cost-effective, with ICERs of -$40.37, -$78.28, and -$135.69 per QALY gained, respectively. NNT of the three strategies were 72, 63, and 55. Screening with a high frequency was associated with higher cost and QALYs; in the probabilistic sensitivity analyses, no matter the initial screening age, screening every 2 years would be the optimal strategy.Conclusion: Screening for H. pylori is a cost-saving and effective way to prevent gastric cancer in China. To prevent more gastric cancer, the population should take an H. pylori test from the age of 20 with a frequency of every 5 years in low gastric cancer incidence areas or age, with a frequency of every 2 years in high gastric cancer incidence areas or age.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AS score: a novel score for predicting clinical outcomes in upper gastrointestinal bleeding.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-01 Epub Date: 2025-01-31 DOI: 10.1080/00365521.2025.2459237

Akif Yarkaç, Seyran Bozkurt, Ataman Köse, Çağrı Safa Buyurgan, Halil Oktay Usluer, Gülhan Temel

{"title":"AS score: a novel score for predicting clinical outcomes in upper gastrointestinal bleeding.","authors":"Akif Yarkaç, Seyran Bozkurt, Ataman Köse, Çağrı Safa Buyurgan, Halil Oktay Usluer, Gülhan Temel","doi":"10.1080/00365521.2025.2459237","DOIUrl":"10.1080/00365521.2025.2459237","url":null,"abstract":"Background: Upper gastrointestinal tract bleeding (UGIB) is an significant cause of admission to emergency departments and hospitalizations.Aims: The aim of our study was to compare the pre-endoscopic risk scores used in the literature with our new score (AS score) in patients admitted to the emergency department due to upper gastrointestinal bleeding (UGIB).Methods: A total of 541 patients admitted to the emergency department of a tertiary care hospital due to UGIB were included in the study. Pre-endoscopic risk scores and AS score were compared in terms of the need for hospitalization, need for intensive care, need for endoscopic treatment, and mortality.Results: All of the scores analysed in the study were found to be effective in predicting the need for hospitalization, the need for intensive care, the need for endoscopic treatment, and mortality. The most effective score in predicting mortality was the AS score. In addition, the sensitivity of the AS score was higher than the other scores in predicting the need for intensive care.Conclusions: The AS score is a new tool that may be useful in the management of patients admitted to the emergency department due to UGIB because of its advantages, such as not including laboratory parameters, being calculated in a very short time in the triage area at the time of patient presentation, and being integrated with the Charlson comorbidity index.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"213-218"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-01 Epub Date: 2025-01-17 DOI: 10.1080/00365521.2025.2453429

Turid Hammer, Frederikke Agerbo Modin, Kári Rubek Nielsen, Jóngerð Midjord, Ebbe Langholz, Vibeke Andersen, Jens Frederik Dahlerup, Jens Kjeldsen, Natalia Pedersen, Pia Munkholm, Johan Burisch

{"title":"Health-related quality of life at diagnosis and follow-up in Faroese and Danish patients with inflammatory bowel disease - a Faroese IBD cohort study.","authors":"Turid Hammer, Frederikke Agerbo Modin, Kári Rubek Nielsen, Jóngerð Midjord, Ebbe Langholz, Vibeke Andersen, Jens Frederik Dahlerup, Jens Kjeldsen, Natalia Pedersen, Pia Munkholm, Johan Burisch","doi":"10.1080/00365521.2025.2453429","DOIUrl":"10.1080/00365521.2025.2453429","url":null,"abstract":"Background and aims: Patients with inflammatory bowel disease (IBD) have lower health-related quality of life (HRQoL) than the general population. The highest incidence and prevalence rates of IBD in the world are found in the Faroe Islands, however, the HRQoL of Faroese patients is unknown. This study aimed to determine their HRQoL at diagnosis and two years of follow-up in comparison with Danish patients.Methods: All patients (15 years or older) were invited to answer the Short Form 12 questionnaire (SF-12) and Short Inflammatory Bowel Disease Questionnaire (SIBDQ) at diagnosis and follow-up. Faroese patients were included from 2010 to 2022, and Danish patients in 2010.Results: 160 Faroese patients and 160 Danish patients completed questionnaires twice. For Faroese patients with IBD, the physical and mental component summary scores (SF-12) significantly improved from 46.6 and 44.0 to 49.4 and 47.7, respectively. Total SIBDQ scores also improved from 46.6 to 53.9. However, Faroese patients had significantly lower scores at diagnosis of social functioning, mental health, and mental component summary (SF-12) as well as lower emotional scores (SIBDQ) compared with Danish patients.Conclusions: Faroese patients with IBD improved their HRQoL from diagnosis to follow-up, although greater improvements were observed for Danish patients. Increased awareness of the HRQoL of this patient group is warranted as Faroese patients had lower mental and emotional scores than Danish patients at diagnosis.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"225-234"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insulin sensitivity in moderately severe to acute severe ulcerative colitis.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-01 Epub Date: 2025-01-30 DOI: 10.1080/00365521.2025.2459870

Daniel Bergemalm, Bayar Baban, Olle Ljungqvist, Jonas Halfvarson

{"title":"Insulin sensitivity in moderately severe to acute severe ulcerative colitis.","authors":"Daniel Bergemalm, Bayar Baban, Olle Ljungqvist, Jonas Halfvarson","doi":"10.1080/00365521.2025.2459870","DOIUrl":"10.1080/00365521.2025.2459870","url":null,"abstract":"Background: Patients hospitalized with moderately severe or acute severe ulcerative colitis (UC) may experience metabolic disturbances, including alterations in insulin resistance due to inflammation and the administration of glucocorticoids (GCs). This pilot study aimed to evaluate insulin sensitivity in patients hospitalized for moderately severe to severe UC.Method: Patients hospitalized for moderately-severely active UC at Örebro University Hospital, Sweden, were eligible for inclusion. Quantification of insulin sensitivity was performed using the hyperinsulinemic euglycemic clamp (HEC) methodology. Assessment of insulin sensitivity was performed during both the index flare and while patients were in steroid-free clinical, biochemical and endoscopic remission during follow-up. Additionally, healthy controls were evaluated using HEC for comparison.Results: Five patients with moderately-severely active UC, treated with intravenous GCs for ≥2 days, were included and underwent HEC assessment. During the index flare, four patients received second-line treatment with infliximab due to non-response to GC, and one patient was subsequently referred for acute subtotal colectomy. At inclusion, all five patients exhibited significantly reduced insulin sensitivity, and levels appeared similar regardless of the outcome of the index flare. At remission during follow-up, the insulin sensitivity was restored to levels comparable to healthy controls (n = 5).Conclusion: The study demonstrates that patients with moderately severe to severe UC experience significant insulin resistance, irrespective of the outcome of the flare. The reduced insulin sensitivity is likely driven by a combination of active inflammation and GC treatment, as insulin sensitivity returned to normal levels when patients achieved remission during follow-up.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"243-247"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Specialty laboratory testing for chronic abdominal pain in irritable bowel syndrome.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-01 Epub Date: 2025-01-24 DOI: 10.1080/00365521.2025.2456491

Michael Cymbal, Arjun Chatterjee, Patricia Ajayi-Fox, Ruishen Lyu, Moises Auron, Brian B Baggott

{"title":"Specialty laboratory testing for chronic abdominal pain in irritable bowel syndrome.","authors":"Michael Cymbal, Arjun Chatterjee, Patricia Ajayi-Fox, Ruishen Lyu, Moises Auron, Brian B Baggott","doi":"10.1080/00365521.2025.2456491","DOIUrl":"10.1080/00365521.2025.2456491","url":null,"abstract":"Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder seen by both primary care providers (PCPs) and gastroenterologists, and further diagnostic testing is generally discouraged unless red-flag symptoms are present.Aims: Examine if advanced serologic testing for chronic abdominal pain in IBS patients followed society-specific guidelines and evaluate the diagnostic accuracy of these tests.Methods: The study involved a retrospective cross-sectional analysis of adults aged 18 and older who were seen at our institution between 2013 and 2018. Tests included: C1 esterase inhibitor, MEFV gene, urine porphobilinogen, anti-dsDNA, and heavy metal screening. Patients with preexisting rheumatological conditions or diagnoses such as hereditary angioedema, porphyria, familial Mediterranean fever, or lead poisoning were excluded. An appropriateness scale based on disease-specific guidelines was used to evaluate test suitability.Results: Among 26,732 IBS patients, 143 underwent advanced laboratory testing, with 85.3% ordered by gastroenterologists. Only 12.5% of tests adhered to society-specific guidelines, and the positive test rate was 2.1%. The total cost of testing was $46,542, with $39,007 spent on tests deemed inappropriate.Conclusions: The findings emphasize the effectiveness and importance of adhering to Rome IV criteria, as advanced testing often fails to improve diagnostic accuracy and increases unnecessary healthcare costs.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"248-252"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143034160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of ELF in predicting liver fibrosis prevalence and fibrosis progression in the general population.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-01 Epub Date: 2025-02-11 DOI: 10.1080/00365521.2025.2454247

Kustaa Saarinen, Martti Färkkilä, Antti Jula, Iris Erlund, Terhi Vihervaara, Annamari Lundqvist, Fredrik Åberg

{"title":"The use of ELF in predicting liver fibrosis prevalence and fibrosis progression in the general population.","authors":"Kustaa Saarinen, Martti Färkkilä, Antti Jula, Iris Erlund, Terhi Vihervaara, Annamari Lundqvist, Fredrik Åberg","doi":"10.1080/00365521.2025.2454247","DOIUrl":"10.1080/00365521.2025.2454247","url":null,"abstract":"Background and aims: The enhanced liver fibrosis (ELF) test has good discrimination performance in detecting advanced liver fibrosis. The chronic liver disease (CLivD) risk score based on clinical data accurately predicts risk for future severe liver disease. Considering the ELF test as a surrogate marker for liver fibrosis, we analyzed predictors of elevated ELF (eELF) and its change.Methods: The study cohort consisted of Finnish general population-based health surveys Health2000 and a follow-up study 10 years later Health2011 with 6084 and 2937 individuals, respectively with phenotype and ELF data. eELF was defined as ELF ≥ 9.8, and clinically relevant fibrosis progression as an ELF change ≥0.6. CLivD risk score was calculated at baseline. Analyses were age-adjusted.Results: Obesity measures and diabetes predicted eELF at baseline. Only waist-hip ratio (WHR) could predict clinically relevant fibrosis progression over the follow-up consistently among men and women (OR 1.35 and 1.41, respectively). High-risk alcohol use was a significant risk factor for eELF only among men (OR 1.72, p = 0.049), and it did not predict fibrosis progression in either sex. Although elevated transaminases were associated with eELF, in most individuals with eELF they were within reference limits. Increased CLivD scores correlated with baseline and the change of ELF values over the 10-year follow-up independent of baseline ELF (p < 0.001).Conclusions: Liver fibrosis progression is difficult to predict based on single risk factors or liver enzymes. ELF had limited value to predict fibrosis progression. The CLivD score, based on multiple risk factors, predicted both occurrence of baseline eELF and its progression over a 10-year follow-up.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"262-272"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prescription of commonly used drugs in patients with functional bowel disorders. A cross-sectional comparison with the general population.

IF 1.6 4区医学

Scandinavian Journal of Gastroenterology Pub Date : 2025-03-01 Epub Date: 2025-01-25 DOI: 10.1080/00365521.2025.2458070

Alice Sandberg-Janzon, Pontus Karling

{"title":"Prescription of commonly used drugs in patients with functional bowel disorders. A cross-sectional comparison with the general population.","authors":"Alice Sandberg-Janzon, Pontus Karling","doi":"10.1080/00365521.2025.2458070","DOIUrl":"10.1080/00365521.2025.2458070","url":null,"abstract":"Objectives: Comorbidity with other conditions is common in functional bowel disorders. We aimed to investigate the prescription patterns of commonly used drugs in patients with irritable bowel syndrome (IBS) and functional unspecific bowel disorder, compared to the general population.Material and methods: Prescriptions of commonly used drugs in 2022 were compared between patients and the general population from the same age group and region in Sweden.Results: Of 526 patients, 317 were followed up in 2022 (219 women and 98 men) and were compared to 51,001 women and 55,571 men in the general population. The median follow-up time from the first visit to 2022 was 8 years (25th-75th percentile 6-11 years). Female patients were significantly more likely than controls to be prescribed PPIs, antibiotics, NSAIDs, paracetamol, opioids, muscle relaxants, antimigraine drugs, antidepressants and asthma medications. Male patients were significantly more likely than controls to be prescribed PPIs, opioids, antidepressants, and asthma medications. In the year prior diagnosis and through 2022, female patients showed a significant decline in the use of PPIs (38% vs.10%; p < 0.001), antibiotics (27.5% vs. 20.1%; p = 0.0426), NSAIDs (23.3% vs.14.6%; p = 0.012), opioids (20.6% vs. 7.5%; p < 0.001), and a significantly increase in the use of asthma medications (15.5% vs. 24.2%; p = 0.0088). Male patients showed a significant decline in the use of PPIs and NSAIDs.Conclusion: Patients with functional bowel disorders are more likely to be prescribed medications for conditions other than IBS. Over time, there was a decline in the prescriptions of most drugs, except for antidepressants and asthma medications.","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"253-261"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143041312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0